Browsing by Author "Plotkin, Scott"

Now showing items 21-40 of 46

    • Improved Tumor Oxygenation and Survival in Glioblastoma Patients Who Show Increased Blood Perfusion After Cediranib and Chemoradiation 

      Batchelor, Tracy; Gerstner, Elizabeth; Emblem, Kyrre E.; Duda, Dan; Kalpathy-Cramer, Jayashree; Snuderl, Matija; Ancukiewicz, Marek; Polaskova, Pavlina; Pinho, Marco C.; Jennings, Dominique; Plotkin, Scott; Chi, Andrew S.; Eichler, April; Dietrich, Jorg; Hochberg, Fred H.; Lu-Emerson, Christine; Iafrate, Anthony; Ivy, S. Percy; Rosen, Bruce; Loeffler, Jay; Wen, Patrick; Sorenson, A. Greg; Jain, Rakesh (National Academy of Sciences, 2013-11-19)
      Antiangiogenic therapy has shown clear activity and improved survival benefit for certain tumor types. However, an incomplete understanding of the mechanisms of action of antiangiogenic agents has hindered optimization and ...

    • Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth 

      James, Marianne; Lelke, Johanna M.; MacCollin, Mia; Plotkin, Scott Randall; Stemmer-Rachamimov, Anat; Ramesh, Vijaya; Gusella, James Francis (Elsevier BV, 2008)
      Meningiomas, common tumors arising from arachnoidal cells of the meninges, may occur sporadically, or in association with the inherited disorder, neurofibromatosis 2 (NF2). Most sporadic meningiomas result from NF2 ...

    • Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2 

      Stivaros, Stavros M; Stemmer-Rachamimov, Anat O; Alston, Robert; Plotkin, Scott R; Nadol, Joseph B; Quesnel, Alicia; O'Malley, Jennifer; Whitfield, Gillian A; McCabe, Martin G; Freeman, Simon R; Lloyd, Simon K; Wright, Neville B; Kilday, John-Paul; Kamaly-Asl, Ian D; Mills, Samantha J; Rutherford, Scott A; King, Andrew T; Evans, D Gareth (BMJ Publishing Group, 2015)
      Background: Neurofibromatosis Type 2 (NF2) is a dominantly inherited tumour syndrome with a phenotype which includes bilateral vestibular (eighth cranial nerve) schwannomas. Conventional thinking suggests that these tumours ...

    • Natural History of Vestibular Schwannoma Growth and Hearing Decline in Newly Diagnosed Neurofibromatosis Type 2 Patients 

      Plotkin, Scott Randall; Merker, Vanessa; Muzikansky, Alona; Barker, Frederick George; Slattery, William (Ovid Technologies (Wolters Kluwer Health), 2014)
      Objective: To determine the rate of growth in vestibular schwannomas and the rate of hearing decline in neurofibromatosis type 2 (NF2) patients not undergoing active treatment Study Design: Prospective study. Setting: ...

    • NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth 

      James, Marianne; Han, S; Polizzano, Carolyn; Plotkin, Scott Randall; Manning, Brendan D.; Stemmer-Rachamimov, Anat; Gusella, James Francis; Ramesh, Vijaya (American Society for Microbiology, 2009)
      Inactivating mutations of the neurofibromatosis 2 (NF2) gene, NF2, result predominantly in benign neurological tumors, schwannomas and meningiomas, in humans; however, mutations in murine Nf2 lead to a broad spectrum of ...

    • Outcomes of preimplantation genetic diagnosis in neurofibromatosis type 1 

      Merker, Vanessa; Murphy, Timothy P.; Hughes, J. Bryan; Muzikansky, Alona; Hughes, Mark Stephen; Souter, Irene C.; Plotkin, Scott Randall (Elsevier BV, 2015)
      Objective To examine the effect of patient and facility level factors on the success of preimplantation genetic diagnosis (PGD) in patients with neurofibromatosis 1 (NF1). Design Retrospective review. Setting Large ...

    • A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer 

      Jackman, David M.; Cioffredi, Leigh A.; Jacobs, Lorraine; Sharmeen, Farhana; Morse, Linda K.; Lucca, Joan; Plotkin, Scott R.; Marcoux, Paul J.; Rabin, Michael S.; Lynch, Thomas J.; Johnson, Bruce E.; Kesari, Santosh (Impact Journals LLC, 2015)
      Introduction: There are few effective treatment options for leptomeningeal metastasis (LM) in non-small-cell lung cancer (NSCLC). This study assessed the feasibility of high-dose gefitinib in patients with LM from NSCLC ...

    • Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide 

      Gerstner, Elizabeth Robins; Eichler, April Fitzsimmons; Plotkin, Scott Randall; Drappatz, Jan; Doyle, Colin L.; Xu, Lei; Duda, Dan Gabriel; Wen, Patrick Yung Chih; Jain, Rakesh K.; Batchelor, Tracy Todd (Springer Nature, 2010)
      Targeting angiogenesis in glioblastoma (GBM) may improve patient outcome by normalizing tumor vasculature and improving delivery of chemotherapeutics and oxygen. Consequently, concomitant administration of small molecule ...

    • Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma 

      Batchelor, Tracy Todd; Duda, Dan Gabriel; di Tomaso, Emmanuelle; Ancukiewicz, Marek; Plotkin, Scott Randall; Gerstner, Elizabeth Robins; Eichler, April Fitzsimmons; Drappatz, Jan; Hochberg, Fred; Benner, Thomas; Louis, David N.; Cohen, Kenneth S.; Chea, Houng; Exarhopoulos, Alexis; Loeffler, Jay Steven; Moses, Marsha; Ivy, Percy; Sorensen, A; Wen, Patrick Yung Chih; Jain, Rakesh K. (American Society of Clinical Oncology (ASCO), 2010)
      Purpose Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in patients with recurrent glioblastoma. ...

    • Phase II Study of Monthly Pasireotide LAR (SOM230C) for Recurrent or Progressive Meningioma 

      Norden, A. D.; Ligon, Keith Lloyd; Hammond, Samantha N.; Muzikansky, A.; Reardon, David Allen; Kaley, Thomas J.; Batchelor, Tracy Todd; Plotkin, Scott; Raizer, Jeffrey J.; Wong, Eric T.; Drappatz, Jan; Lesser, Glenn J.; Haidar, Sam; Beroukhim, Rameen; Lee, Eudocia Quant; Doherty, Lisa; Lafrankie, Debra; Gaffey, S. C.; Gerard, Mary; Smith, Katrina H.; McCluskey, C.; Phuphanich, Surasak; Wen, Patrick Yung Chih (Ovid Technologies (Wolters Kluwer Health), 2014)
      Objective: A subset of meningiomas recur after surgery and radiation therapy, but no medical therapy for recurrent meningioma has proven effective. Methods: Pasireotide LAR is a long-acting somatostatin analog that may ...

    • Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosis 

      Smith, Miriam J.; Esparza, Sonia; Merker, Vanessa; Muzikansky, Alona; Bredella, Miriam A.; Harris, Gordon J.; Kassarjian, Ara; Cai, Wenli; Walker, James Anthony; Mautner, Victor F.; Plotkin, Scott Randall (Elsevier BV, 2013)
      Objectives Neurofibromatosis 1 (NF1), NF2, and schwannomatosis are characterized by a predisposition to develop multiple neurofibromas and schwannomas. Currently, there is no blood test to estimate tumor burden in ...

    • Pregnancy complications in women with rare tumor suppressor syndromes affecting central and peripheral nervous system 

      Terry, Anna R.; Merker, Vanessa; Barker, Frederick George; Leffert, Lisa Rae; Bateman, Brian Thomas; Souter, Irene C.; Plotkin, Scott Randall (Elsevier BV, 2015)
      Neurofibromatosis type 2 (NF2), tuberous sclerosis (TS), and von Hippel-Lindau disease (VHL) are tumor suppressor syndromes characterized by multiple benign tumors of the peripheral and central nervous system.1 These tumors ...

    • Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature 

      Vranceanu, Ana-Maria; Merker, Vanessa; Park, Elyse Richelle; Plotkin, Scott Randall (Springer Nature, 2013)
      The aim of this study was to review the literature on quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis, and to identify the specific aspects of quality of life that ...

    • Quantitative Assessment of Whole-Body Tumor Burden in Adult Patients with Neurofibromatosis 

      Plotkin, Scott Randall; Bredella, Miriam A.; Cai, Wenli; Kassarjian, Ara; Harris, Gordon J.; Esparza, Sonia; Merker, Vanessa L.; Munn, Lance Leon; Muzikansky, Alona; Askenazi, Manor; Nguyen, Rosa; Wenzel, Ralph; Mautner, Victor F. (Public Library of Science (PLoS), 2012)
      Purpose Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis are at risk for multiple nerve sheath tumors and premature mortality. Traditional magnetic resonance imaging (MRI) has limited ability to assess ...

    • Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme 

      Reardon, David Allen; Fink, Karen L.; Mikkelsen, Tom; Cloughesy, Timothy F.; O, Alison; Plotkin, Scott Randall; Glantz, Michael; Ravin, Paula; Raizer, Jeffrey J.; Rich, Keith M.; Schiff, David; Shapiro, William R.; Burdette-Radoux, Susan; Dropcho, Edward J.; Wittemer, Sabine M.; Nippgen, Johannes; Picard, Martin; Nabors, L. Burt (American Society of Clinical Oncology (ASCO), 2008)
      Purpose Cilengitide, an inhibitor of αvβ3 and αvβ5 integrin receptors, demonstrated minimal toxicity and durable activity across a wide range of doses administered to adults with recurrent glioblastoma multiforme (GBM) ...

    • Recommendations for imaging tumor response in neurofibromatosis clinical trials 

      Dombi, E.; Ardern-Holmes, S. L.; Babovic-Vuksanovic, D.; Barker, Frederick George; Connor, S.; Evans, D. G.; Fisher, Marc; Goutagny, S.; Harris, G. J.; Jaramillo, D.; Karajannis, M. A.; Korf, B. R.; Mautner, V.; Plotkin, Scott Randall; Poussaint, Tina Young; Robertson, Kent; Shih, C.-S.; Widemann, B. C.; undefined, undefined (Ovid Technologies (Wolters Kluwer Health), 2013)
      Objective: Neurofibromatosis (NF)-related benign tumors such as plexiform neurofibromas (PN) and vestibular schwannomas (VS) can cause substantial morbidity. Clinical trials directed at these tumors have become available. ...

    • Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis 

      Merker, Vanessa; Bredella, Miriam A.; Cai, Wenli; Kassarjian, Ara; Harris, Gordon J.; Muzikansky, Alona; Nguyen, Rosa; Mautner, Victor F.; Plotkin, Scott Randall (Wiley-Blackwell, 2014)
      Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis share a predisposition to develop multiple nerve sheath tumors. Previous studies have demonstrated that patients with NF1 and NF2 have reduced quality of ...

    • Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1 

      Plotkin, Scott Randall; Davis, Stephanie H.; Robertson, Kent A.; Akshintala, Srivandana; Allen, Julian; Fisher, Michael J.; Blakeley, Jaishri O.; Widemann, Brigitte C.; Ferner, Rosalie E.; Marcus, Carole L. (Ovid Technologies (Wolters Kluwer Health), 2016)
      Objective: Plexiform neurofibromas (PNs) are complex, benign nerve sheath tumors that occur in approximately 25%–50% of individuals with neurofibromatosis type 1 (NF1). PNs that cause airway compromise or pulmonary dysfunction ...

    • Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma 

      Plotkin, Scott Randall; Halpin, Chris; Blakeley, Jaishri O.; Slattery, William H.; Welling, Duane Bradley; Chang, Susan M.; Loeffler, Jay Steven; Harris, Gordon J.; Sorensen, A; McKenna, Michael John; Barker, Frederick George (Springer Nature, 2009)
      Neurofibromatosis type 2 (NF2) is a tumor suppressor gene syndrome characterized by multiple schwannomas, especially vestibular schwannomas (VS), and meningiomas. Anticancer drug trials are now being explored, but there ...

    • Teaching NeuroImages: Brain mass with hilar adenopathy: The importance of histologic diagnosis 

      Jordan, Justin Thomas; Yang, Hyun-Sik; Narendra, Derek; Plotkin, Scott Randall (Ovid Technologies (Wolters Kluwer Health), 2014)